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ABSTRACT
Background. We report the histopathological results of a
novel ‘‘inversed’’ strategy designed to manage patients
with colorectal cancer (CRC) who have synchronous liver
metastases by using chemotherapy first, liver surgery sec-
ond, and resection of the primary tumor as a final step. This
study was designed to compare the response to chemo-
therapy in liver metastases, primary tumors, and
locoregional lymph nodes.
Methods. Twenty-nine patients with stage IV CRC
received a combination of oxaliplatin, irinotecan, 5-fluo-
rouracil, and leucovorin (OCFL) for 3–4 months.
Histological response to chemotherapy was assessed by
using a tumor regression grading (TRG) score based on
presence of residual tumor cells and extent of fibrosis.
Results. Median age of patients was 56 (range, 37–69)
years. Primary tumor location was right colon (n = 5), left
colon (n = 7), and rectum (n = 17 patients). TRG scores
correlated across disease sites (Spearman correlation
coefficients for TRG in the primary tumor and lymph nodes
was 0.59 [P = 0.005]; for the primary tumor and metas-
tases 0.44 [P = 0.021]; and for lymph nodes and
metastases 0.58 [P = 0.006]). Complete absence or poor
tumor response (TRG4/5) was significantly more frequent
in primary tumors (35.7%) and locoregional lymph nodes
(38%) than in liver metastases (6.9%; McNemar test,
P = 0.02). Two patients had a complete pathologic
response (pT0N0M0).
Conclusions. In patients with stage IV colorectal cancer,
liver metastases exhibit a better histological response than
primary tumors to OCFL neoadjuvant chemotherapy.
Standard management of colorectal cancer (CRC) cur-
rently consists in resection of the primary tumor, followed
by adjuvant chemotherapy for stage III and high-risk stage
II patients. For patients with colon cancer, there is no
controversy regarding the chronological order of these
components. Surgery is performed first, and decision
regarding adjuvant chemotherapy is based on histopathol-
ogical examination of the surgical specimen.1 It is therefore
not surprising that by contrast with rectal cancer patients
(who usually benefit from neoadjuvant chemoradiation),
the response of colon cancer patients to neoadjuvant
chemotherapy has rarely been reported. However, the
development of novel multimodality strategies designed to
curatively manage patients with stage IV CRC has recently
provided an opportunity to address this issue.2,3
Since 1999, an inversed strategy for managing stage IV
colorectal cancer patients presenting with synchronous
liver metastases has been developed at our institution.4 In
this protocol, chemotherapy (a combination of oxaliplatin,
irinotecan, 5-fluorouracil, and leucovorin [OCFL]) is
administered first, followed by resection of liver metas-
tases, and primary tumor resection is performed as the last
step.5 The design of this protocol provides clinicians and
pathologists with the opportunity to examine and compare
the pathologic response to neoadjuvant chemotherapy in
liver metastases, primary tumor, and regional lymph
nodes.
 Society of Surgical Oncology 2010
First Received: 28 December 2008;
Published Online: 20 April 2010
G. Mentha
e-mail: gilles.mentha@hcuge.ch
Ann Surg Oncol (2010) 17:2714–2719
DOI 10.1245/s10434-010-1056-6
Histological tumor response has more than a morpho-
logical interest and is directly correlated with disease-free
and overall survival in patients with breast carcinomas
and osteosarcoma.6,7 It was recently demonstrated that
pathologic response after neoadjuvant chemotherapy and
resection of hepatic metastases is an independent predictor
of 5-year overall survival in patients with stage IV CRC.8,9
Moreover, histological tumor response in liver metastases
was directly affected by the chemotherapy regimen, with
an increased response rate in patients who received oxa-
liplatin and irinotecan in addition to 5-fluorouracil (5-FU)
and leucovorin. This combination neoadjuvant chemo-
therapy regimen has markedly improved the outcome of
patients with CRC who have unresectable liver metastases,
and it is tempting to hypothesize that its impact on primary
tumors might be even more dramatic.10
From a biological standpoint, the current consensus is
that secondary tumors result from nonrandom selection of a
clonal population within the primary.11 It is expected that
liver metastases demonstrate a more aggressive phenotype
and are more resistant to treatment, because they remain
the cause of 90% of deaths from solid tumors.12 Another
aspect of response to chemotherapy is the role of organ
microenvironment, which provides the secondary tumors
with neovessels and might increase the delivery of che-
motherapy to highly vascularised metastases.13 This study
was designed to assess and compare the histological
responses of primary CRC and liver metastases to a stan-
dardized chemotherapy protocol. We postulated that
primary and metastatic CRC—although both chemosensi-
tive—would differ in their response to chemotherapy; our
working hypothesis was that primary tumors would exhibit
a better response to OCFL than liver metastases.
METHODS
The following data regarding 29 consecutive patients
with histology-proven adenocarcinoma of the colon or
rectum and synchronous liver metastases were prospec-
tively entered into a computerized database: patients’
demographics; American Society of Anesthesiology (ASA)
classification of operative risk; TNM classification and the
site of the primary; presence of extrahepatic tumoral sites;
clinical risk score (CRS) according to Fong’s classification;
location and number of liver metastases; chemotherapy
performed prior and after surgery; radiation therapy to the
pelvis for rectal cancer; type and complications related to
liver resection; and the details of resection of the primary
tumor, including postoperative course and complications.
All patients included in this study presented with advanced
liver disease and underwent preoperative portal emboliza-
tion and/or two-stage hepatectomy.
Neoadjuvant Chemotherapy
Twenty-eight of 29 patients received two to six cycles of
chemotherapy before liver resection, using a combination
of oxaliplatin [O], irinotecan (CPT-11[C]), 5-FU [F], and
leucovorin [L], according to the following doses and
schedule: oxaliplatin 70 mg/m2 on days 1 and 15, irino-
tecan (CPT-11) 100 mg/m2 on days 8 and 22, 5-FU 2 g/m2/
24 h, and leucovorin (LV) 30 mg on days 1, 8, 15, and 22,
repeated every 5 weeks, as described previously.5 Seven
patients had a similar regimen but with 5-FU/LV replaced
with capecitabine (the oral prodrug of 5-FU) 800 mg/m2
per day from day 1 to day 28. One patient received
standard treatment with capecitabine and oxaliplatin
(capecitabine 2 g/m2, oxaliplatin 130 mg/m2 day 1, days
1–14, repeated every 3 weeks). The response to chemo-
therapy was assessed after two to three cycles. Further
evaluations were obtained according to the clinical
response and surgical pattern of disease. Additional cycles
were given if a further response was likely to confer a
surgical advantage. More recently, eight patients were
treated with the addition of bevacizumab (Avastin) and
two other patients received cetuximab (Erbitux) to com-
plement OCFL regimen. All patients gave informed,
written consent before receiving the chemotherapy proto-
col, which was approved by the ethics committee of our
institution.
Surgery
Simultaneous colonic and liver resections were per-
formed in selected circumstances (right colon or \1–2
segments and left colon), but rectal resections and complex
liver resections were not performed during the same
operation. According to our protocol, when staged resec-
tions were planned, liver resection was always performed
first and colorectal resection second, with ideally a short
(4–6 weeks) interval between the two procedures. For
patients with rectal cancer, neoadjuvant radiation therapy
to the pelvis, when indicated, was delivered for 5.5 weeks
(28 9 1.5 Gy), and rectal surgery was performed 6 weeks
later. The resection of all liver metastases was planned not
only on the most recent CT scan or MRI but also on the CT
scan before chemotherapy was started, to avoid leaving
‘‘missing metastases’’ behind.
Histopathological Assessment
Histological response to chemotherapy was assessed
using a tumor regression grading (TRG) score based on the
presence of residual tumor cells and the extent of fibrosis.
Adequate assessment of the whole tumor (both primary and
metastatic) specimen was performed by assessing TRG in
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multiple tissues samples according to a previously descri-
bed protocol.8 Briefly, hepatectomy specimens were
sectioned in 5-mm–thick slices. In patients with multiple
liver metastases, each lesion was extensively sampled from
the center to the periphery to include multiple sections of
tumor and liver parenchyma. More than one section per
centimeter was reviewed from each tumor nodule. All
tumors measuring \1 cm and/or exhibiting complete
pathologic response were entirely submitted for micro-
scopic examination. This grading system is similar to the
Mandard protocol, which was initially elaborated for
assessing response to neoadjuvant radiochemotherapy in
esophageal carcinomas.14 More recently, this standardized
protocol was extended to rectal carcinomas; TRG1 corre-
sponded to absence of tumor cells replaced by abundant
fibrosis, TRG2 to rare residual tumor cells scattered
throughout abundant fibrosis, TRG3 to more residual tumor
cells throughout a predominant fibrosis, TRG4 to large
amount of tumor cells predominating over fibrosis, and
TRG5 most exclusively to tumor cells without fibrosis15
(Fig. 1).
Statistical Analysis
Statistical analyses were undertaken by means of the
software package STATGRAPH 3.0 software for Windows
(Statgraph Software Inc., San Diego, CA). Quantitative
data were expressed as median (range). Groups’ compari-
sons were made using chi-square or Fisher’s exact test for
categorical variables, and Student’s t test, or Mann–Whit-
ney U for continuous variables. To assess correlations
between TRG scores across disease sites (primary site,
lymph nodes, metastases), we obtained Spearman correla-
tion coefficients. We also dichotomized TRG results as
good (scores 1–3) versus poor (scores 4 or 5) and compared
probabilities of poor response across disease sites using
McNemar tests. Two-sided P values B0.05 were consid-
ered statistically significant.
RESULTS
Between January 2001 and July 2008, 29 patients with
stage IV CRC completed our therapeutic protocol. Median
age of patients was 56 (range, 37–69) years. Primary tumor
location was right colon (n = 5), left colon (n = 7), and
rectum (n = 17 patients). Median number of liver metas-
tases was 5 (range, 1–21). Eight patients underwent a one-
step procedure, with simultaneous resection of the primary
tumor and liver metastases. Twenty-one patients underwent
a staged procedure due to an extended hepatectomy or
rectal location of the primary. In this group, median delay
between liver surgery and resection of the primary tumor
was 70 (range, 20–280) days. Characteristics of patients’
demographics, as well as primary and metastatic tumor
locations, are summarized in Table 1. Of 29 patients, 16
are still alive and 13 are free of recurrence; median survival
for the entire group was 44 months, and overall 1-, 3-, and
5-year survival rates were 100%, 60%, and 31%,
respectively.
TRG scores were available for all metastases, as well as
21 node-positive primary tumors. Data regarding primary
tumor TRG were missing for one patient who underwent
primary tumor surgery in another institution. TRG scores
according to location are illustrated in Table 2. TRG scores
on a 1 to 5 scale were moderately correlated across disease
sites: the Spearman correlation coefficient for TRG in
primary tumor and lymph nodes was 0.59 (P = 0.005); for
FIG. 1 The grading system is based on a
quantitative morphologic assessment of fibrosis
versus residual tumor cells within tumor
deposits. Grade 1 indicates complete response
with maximal fibrosis, and no residual tumor
cells, whereas grade 5 indicates a complete
absence of fibrosis
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primary tumor and metastases 0.44 (P = 0.021); and for
lymph nodes and metastases 0.58 (P = 0.006).
Complete absence or poor tumor response (TRG4/5)
was significantly more frequent in primary tumors (35.7%)
and regional lymph nodes (38%) than liver metastases
(6.9%) (McNemar test, P = 0.02; Fig. 2). TRG5 (null
response) was rare in liver metastases (3.4%) and primary
tumors (0%) but was detected in 19% of N ? tumors. In
two patients, the final diagnosis was pT0N1, indicating a
better response in the primary tumors than in the locore-
gional lymph nodes. Two patients (6.9%) had a complete
pathologic response (pT0N0M0). Interestingly, both ini-
tially presented with advanced rectal cancer, but one of
them did not undergo preoperative radiation therapy and
demonstrated complete response with chemotherapy alone.
DISCUSSION
The data presented here indicate that primary and met-
astatic CRC differ in their response to neoadjuvant
combination chemotherapy, consisting of oxaliplatin, iri-
notecan, 5-fluorouracil and leucovorin. Poor tumor
response (TRG4/5) was significantly more frequent in
primary tumors (35.7%) and locoregional lymph nodes
(38%) than liver metastases (6.9%). Of five tumor speci-
mens that showed complete absence of response (TRG5),
four (80%) were located within locoregional lymph nodes.
Complete pathologic response (pT0N0M0) was reported in
two (6.9%) patients.
The TRG score used in this series has been validated in
CRC patients, not only as a morphologic variable to assess
response to neoadjuvant chemo- or radiotherapy, but also
as a prognostic factor for disease-free and overall sur-
vival.16 The high histological response rates in this series
are likely to result from the combination of oxaliplatin and
TABLE 1 Patient and tumor characteristics
Variable N = 29
Patients
Female 12
Male 17
Primary tumor location
Right colon 5
Left colon 7
Rectum 17
Metastases distribution
Unilobar 10
Bilobar 19
Chemotherapy regimen
Oxaliplatin 29
Irinotecan 28
5-fluorouracil 29
Leucovorin 23
Bevacizumab 8
Cetuximab 2
Pelvic irradiation for rectal cancer
Yes 8
No 9
Timing hepatectomy-colectomy
Synchronous 8
Staged 21
Final pathologic stage primary tumor
T0 4
T1 0
T2 4
T3 18
T4 3
Final pathologic stage metastases
M0 3
M1 26
Status at last follow-up
Dead 13
Alive with disease recurrence 3
Alive with no evidence of disease 13
TABLE 2 Tumor response according to location
Site
TRG Liver
metastases
Locoregional
lymph nodesa
Primary
tumorb
1–2 major response 11 8 10
3 16 5 8
4–5 poor response 2 8 10
a 21 tumors only were N?
b One patient’s data missing (primary tumor surgery performed in
another institution)
30
25
20
15
10
5
p = 0.02
Poor tumor
response
Primary
Tumors
Locoregional
lymph nodes
Liver
Metastases
FIG. 2 Poor tumor response (TRG4/5) was significantly more
frequent in primary tumors (T = 35.7%) and locoregional lymph
nodes (N = 38%) than liver metastases (M = 6.9%) (McNemar test,
P = 0.02)
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irinotecan; the vast majority (96.5%) of patients who
received both drugs had TRG1-3 scores in their liver
metastases. In addition, we report the results of a selected
group of patients who responded to neoadjuvant chemo-
therapy and eventually underwent liver and colorectal
surgery with curative intent.17 This being considered, our
data are in line with phase III trials, which have demon-
strated clinical response rates in the 40–50% range for both
oxaliplatin- and irinotecan-based regimens.18 Thus, path-
ologic response to chemotherapy is progressively
emerging, not only as a mere morphologic variable, but as
a new prognostic parameter after surgery for CRC, whether
or not it is metastatic.19
The better histological response rate in liver metastases
than in primary tumors, as reported here, is intriguing, but
probably results from the combination of two factors. First,
a better drug delivery might be responsible for higher
concentrations of cytotoxics drugs within the liver than in
the colon and its mesentery. The histological demonstration
of specific alterations in the hepatic parenchyma adjacent
to metastases, such as oxaliplatin-related sinusoidal
obstruction syndrome and irinotecan-related steatohepati-
tis, provides indirect evidence that these drugs are present
in high concentration within the liver.20,21 In other words,
the histological differences in response to OCFL are
probably related more to the tumor microenvironment than
to tumor cell chemosensitivity; the liver, with its dense
vascular sinusoidal network, provides an excellent delivery
access to metastases, which are dependent upon sinusoidal
endothelial cells for their growth.22
The second explanation for these differences is related
to the schedule of chemotherapy administration; after
exclusion of 8 patients who underwent synchronous liver
and colonic surgery, there was a median delay of 70 (range,
20–280) days between liver and colorectal surgery in 21
other patients. We hypothesize that this interval is a ther-
apeutic window during which repopulation of cancer cells
may occur within the primary tumor.23 Whereas little is
known about tumor repopulation during chemotherapy, we
have observed similar instances of tumor progression in
patients who underwent two-step hepatectomy.24 We now
try to reduce as much as possible the time interval between
the two procedures, and we believe that colorectal surgery
should ideally be performed 4 weeks after hepatectomy,
except for rectal cancer patients who might benefit from
neoadjuvant radiation therapy. In our series, seven patients
had the two operations performed with an interval of 20–
40 days. Of note, a laparoscopic approach for colorectal
surgery is feasible and in some patients might contribute to
reducing the surgical trauma of the second operation.
Our results also demonstrate an identical poor response
rate for primary tumors and locoregional lymph nodes
(*36%). Approximately one-third of primary tumors were
classified as TRG4/5. Regional lymph nodes seem to har-
bor the most resistant tumor deposits—a fact that, again,
might reflect a lower concentration of cytotoxic drugs in
the mesocolon. This finding is highly relevant and trans-
lated clinically into the occasional occurrence (2 patients)
of complete pathological response in the primary, but with
residual tumor detected within regional lymph nodes
(pT0N1).25 Interestingly, two studies that focused on
patients with T3-T4 rectal cancer downstaged by neoad-
juvant chemoradiation to pT0 reported a 17% rate of
positive mesorectal lymph nodes.26,27 Finally, two other
patients had a complete pathologic response (pT0N0M0)—
a low incidence (6.9%) similar to what was observed in
liver metastases by Adam et al. (4%).28
In conclusion, primary and secondary tumors differ in
their response to neoadjuvant chemotherapy, but hepatic
metastases exhibit better histological response rates despite
being, in theory, phenotypically more aggressive. This
unexpected finding, if confirmed by other series using
similar chemotherapy regimen, warrants further investiga-
tion. Until then, we postulate that high concentrations of
oxaliplatin and irinotecan within the hepatic sinusoids are
responsible for both positive (high rates of tumor response)
and negative (sinusoidal obstruction syndrome) histologi-
cal alterations within liver metastases and surrounding
hepatic parenchyma, respectively.
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